Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
Cancer Immunology, Immunotherapy · 19.03.2025 · 74 (5)
DOI: 10.1007/s00262-025-04005-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.03.2025. Verfasst von Eunyoung Tak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Immunotherapy, Protein Kinase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Bio & Medical Technology Development Program of the NRF, Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Oncology, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea.
- Department of Radiation Oncology, Asan Preclinical Evaluation Center for Cancer TherapeutiX, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Oncology, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea. jeongeunkim@amc.seoul.kr.
- Asan Preclinical Evaluation Center for Cancer TherapeutiX, Asan Medical Center, Seoul, 05505, Republic of Korea.
ORCID-Profile: Jeong Eun Kim
Förderung
- National Research Foundation of Korea
- Bio & Medical Technology Development Program of the NRF
- Ministry of Health & Welfare, Republic of Korea
- Ministry of Science and ICR
- Health Technology R&D Project through the Korea Health Industry Development Institute
Zitieren
APA
Tak, E., An, H. I., Lee, A. S., Han, K., Choi, J., Kim, H. D., Hong, Y. S., Kim, S. Y., Choi, E. K., Kim, J. E., & Kim, T. W. (2025). Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer. Cancer Immunology, Immunotherapy, 74(5). https://doi.org/10.1007/s00262-025-04005-3
Vancouver
Tak E, An HI, Lee AS, Han K, Choi J, Kim HD, et al. Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer. Cancer Immunology, Immunotherapy. 2025;74(5). doi:10.1007/s00262-025-04005-3
BibTeX
@article{Tak2025,
author = {Tak, Eunyoung and An, Hye-In and Lee, Amy Sinyoung and Han, Kyuyoung and Choi, Jiwan and Kim, Hyung-Don and Hong, Yong Sang and Kim, Sun Young and Choi, Eun Kyung and Kim, Jeong Eun and Kim, Tae Won},
title = {Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {5},
doi = {10.1007/s00262-025-04005-3}
}
EUVIMED